Definition
Emraclidine is an investigational small‑molecule drug that acts as a selective positive allosteric modulator (PAM) of the muscarinic acetylcholine receptor M1 (M1 mAChR). It is being studied for the potential treatment of neuropsychiatric disorders, principally schizophrenia.
Overview
Emraclidine, also designated CVL‑231 during its development, is being developed by Vanda Pharmaceuticals. Preclinical studies demonstrated that it enhances M1 receptor signaling without directly activating the receptor, thereby aiming to improve cognitive and negative symptoms associated with schizophrenia while minimizing peripheral cholinergic side effects. As of the latest publicly available information, emraclidine has progressed to Phase 2 clinical trials, where its safety, tolerability, and efficacy are being evaluated in patients with schizophrenia. The compound is administered orally.
Etymology / Origin
The name “emraclidine” follows pharmaceutical naming conventions, combining the stem “‑clidine,” commonly used for central nervous system agents, with a prefix that likely reflects the developer’s internal code (e.g., “emra‑”). No further etymological details have been disclosed by the manufacturer.
Characteristics
- Chemical class: Small‑molecule positive allosteric modulator of the muscarinic M1 receptor.
- Mechanism of action: Binds to an allosteric site on M1 mAChR, increasing the receptor’s response to endogenous acetylcholine without directly stimulating the receptor. This selectivity is intended to target central cholinergic pathways implicated in cognition and psychosis.
- Pharmacokinetics: Reported to have oral bioavailability with a half‑life supporting once‑daily dosing; specific metabolic pathways have not been fully disclosed in peer‑reviewed literature.
- Clinical development: Completed Phase 1 trials demonstrating acceptable safety and pharmacodynamic activity. Ongoing Phase 2 trials assess efficacy in reducing positive and negative symptoms of schizophrenia. No regulatory approval has been granted as of the latest update.
- Safety profile: Preliminary data indicate a tolerable safety profile with the most common adverse events being mild gastrointestinal symptoms; comprehensive safety data await publication from Phase 2 studies.
Related Topics
- Muscarinic acetylcholine receptors (M1 subtype)
- Positive allosteric modulators (PAMs)
- Schizophrenia pharmacotherapy
- Vanda Pharmaceuticals
- CVL‑231 (development code for emraclidine)
- Cognitive deficits in neuropsychiatric disorders
Note: All information presented reflects the current publicly available data on emraclidine. Ongoing clinical trials may provide additional insights that could modify the described characteristics.